David Mongan reports on a recent trial of omega-3 supplementation for the prevention of psychosis in people at ultra-high risk, which finds no evidence of a positive effect. He reflects on these findings and considers what’s next for the field.
[read the full story...]The role of the gut microbiome in treatment-resistant schizophrenia
Nuala Murray explores a recent Australian case-control study that looks at the associations between changes in gut microbiota and schizophrenia diagnosis, treatment resistance, and clozapine response.
[read the full story...]Antidepressants: what is the Smallest Worthwhile Difference?
Linda Gask summarises findings from a cross-sectional online survey that investigated the Smallest Worthwhile Difference necessary for individuals with depression to consider taking antidepressants.
[read the full story...]Is anxiety a gateway to other mental health problems? Comorbidities with depression and other anxiety disorders
Nina Higson-Sweeney summarises a study using data from the UK-based GLAD and COPING NBR cohorts to investigate factors associated with anxiety disorder comorbidity with anxiety and depression.
[read the full story...]Clinical severity and instability as predictors for psychiatric hospitalisation: can one size fit all?
Florian Walter summarises a retrospective cohort study published in The Lancet Psychiatry that investigates whether early trajectories of clinical global impression severity can transdiagnostically predict later psychiatric hospitalisation.
[read the full story...]